Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 4Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 152Breast Neoplasms 146Neoplasms 143Neoplasm Metastasis 142Colorectal Neoplasms 137Recurrence 105Ovarian Neoplasms 101Pancreatic Neoplasms 83Advanced Solid Tumor 82Lung Neoplasms 81Multiple Myeloma 77Prostatic Neoplasms 75Advanced Solid Tumors 74Stomach Neoplasms 73Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 68Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 64Triple Negative Breast Neoplasms 59Lymphoma, B-Cell 55Endometrial Neoplasms 54Myelodysplastic Syndromes 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma 52Glioma 51Brain Neoplasms 46Carcinoma, Renal Cell 44Hematologic Neoplasms 43

Interventions

sodium thiosulfate 1Platinum 1Magnetic Resonance Spectroscopy 1Hearing 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Seminoma × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡